<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254031</url>
  </required_header>
  <id_info>
    <org_study_id>1191.3</org_study_id>
    <nct_id>NCT02254031</nct_id>
  </id_info>
  <brief_title>Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>An Open Phase I Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously Once Per Week for Three Weeks in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer With Repeated Administration Courses in Patients With Clinical Benefit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>July 2003</start_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
    <description>graded according to common toxicity criteria (CTC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant findings in laboratory examinations</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant findings in vital signs</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with development of Human Anti-Human Antibody (HAHA)</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration time curve from time zero to time point 168 hours (AUC0-168)</measure>
    <time_frame>up to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration time curve from time zero to the time of the last quantifiable drug concentration (AUC0-tz)</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration time curve from time point zero to infinity (AUC0-∞)</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum serum concentration (tmax)</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CL)</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution during the terminal elimination phase (Vz)</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration at steady state (Cpre,ss)</measure>
    <time_frame>up to 7 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum serum concentration during the dosing interval τ at steady state (Cmin,ss)</measure>
    <time_frame>up to 7 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linearity index (LI)</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation factor (RA)</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
    <description>according to response evaluation criteria in solid tumours (RECIST)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>bivatuzumab mertansine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bivatuzumab mertansine</intervention_name>
    <arm_group_label>bivatuzumab mertansine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. female patients aged 18 years or older

          2. patients with breast cancer positive for CD44v6 in at least 50 % of the tumour cells

          3. patients with local and / or regional recurrent disease or distant metastases who are
             refractory to anthracyclines and / or taxanes (unless contraindications to taxanes and
             / or anthracyclines) or not amenable to established treatments

          4. measurable tumour deposits by one or more radiological techniques (MRI, CT)

          5. life expectancy of at least 6 months

          6. Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2

          7. patients must have given written informed consent (which must be consistent with
             International Conference of Harmonisation-Good Clinical Practice (ICH-GCP) and local
             legislation)

        Exclusion Criteria:

          1. hypersensitivity to humanised or murine antibodies, immunoconjugates or the excipients
             of the trial drugs

          2. known secondary malignancy requiring therapy

          3. active infectious disease

          4. brain metastases requiring therapy

          5. neuropathy grade 2 or above

          6. absolute neutrophil count less than 1,500/mm3

          7. platelet count less than 100,000/mm3

          8. bilirubin greater than 1.5 mg/dl (&gt; 26 μmol/L, système internationale (SI) unit
             equivalent)

          9. aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than
             3 times the upper limit of normal

         10. serum creatinine greater than 1.5 mg/dl (&gt; 132 μmol/L, SI unit equivalent)

         11. concomitant non-oncological diseases which are considered relevant for the evaluation
             of the safety of the trial drug

         12. chemo- or immunotherapy within the past four weeks prior to treatment with the trial
             drug or during the trial (except for present trial drug)

         13. radiotherapy to breast and thorax region within the past four weeks prior to treatment
             with the trial drug or during the trial

         14. women who are sexually active and unwilling to use a medically acceptable method of
             contraception

         15. pregnancy or lactation

         16. treatment with other investigational drugs or participation in another clinical trial
             within the past four weeks before start of therapy or concomitantly with this trial
             (except for present trial drug)

         17. patients unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>September 30, 2014</last_update_submitted>
  <last_update_submitted_qc>September 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maytansine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

